# Robbie G. Majzner

Source: https://onco.cc/people/robbie-majzner/  
OnCo record `robbie-majzner` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the GD2 CAR-T trial in diffuse midline glioma and defined antigen density as a barrier to CAR-T in solid tumours.

## Summary

Robbie Majzner was first author of the Nature trial of GD2-directed CAR T cells in H3K27M-mutant diffuse midline glioma, one of the first cell therapies to show activity in a paediatric brain tumour, and led the work showing CAR T cells need high antigen density and that B7-H3 is a broadly expressed paediatric target. He moved from Stanford to lead solid tumour immunotherapy at St. Jude.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cell-therapy; car-t; paediatric
- Role: Director of Solid Tumor Immunotherapy, Department of Oncology, St. Jude Children's Research Hospital
- Specialisms: Paediatric CAR T-cell therapy; Solid tumour immunotherapy; GD2 and B7-H3 targets; CAR engineering

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Majzner%20RG%5BAuthor%5D%20CAR%20T

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/)
- technologies: [Armoured, logic-gated & next-gen CARs](https://onco.cc/technologies/armored-car/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/)
- institutions: [St. Jude Children's Research Hospital](https://onco.cc/institutions/st-jude/)

---
JSON: https://onco.cc/api/v1/entities/robbie-majzner.json